I. Posters Six posters have been accepted for presentation at EASL Congress mainly covering several of GENFIT’s assets positioned in ACLF and, including, GENFIT’s latest work on Real-World data in ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.

In the 10-Q report, 89bio detailed its progress in the development of pegozafermin, particularly in its Phase 3 clinical ...

So, there's this scientist, Arun Sanyal, M.D., who's the director of the VCU Stravitz-Sanyal Institute for Liver Disease and ...

Mar. 11, 2025 — Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder ... Novel Therapeutics of Nonalcoholic Fatty Liver Diseases Mar. 6, 2025 — Investigators have ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...